Obesity Medicine最新文献

{"title":"Exploring uric acid as a biomarker in lipedema and lymphedema: A metabolomics study with prospective validation","authors":"Fahad Alkhalfan ,&nbsp;Naseer Sangwan ,&nbsp;Anu Aggarwal ,&nbsp;Alliefair Scalise ,&nbsp;José O. Alemán ,&nbsp;Bhairavi Rajasekar ,&nbsp;Douglas Joseph ,&nbsp;Kimberly Peterson ,&nbsp;Annelise Hamer ,&nbsp;Mariya Ali ,&nbsp;John R. Bartholomew ,&nbsp;Scott J. Cameron","doi":"10.1016/j.obmed.2025.100618","DOIUrl":"10.1016/j.obmed.2025.100618","url":null,"abstract":"<div><h3>Aims</h3><div>Lipedema is a condition often mistaken for other causes of limb swelling including lymphedema and obesity. Lipedema may have a unique metabolic profile. Interrogation of the metabolome is a strategy that could reveal unique biomarkers to distinguish lipedema from lymphedema and obesity.</div></div><div><h3>Methods</h3><div>Unbiased metabolomics was utilized to examine 38 BMI-matched overweight patients compared with patients with lipedema, lymphedema, and lipolymphedema. Machine learning identified biomarkers to distinguish diseases, and further examined in a validation cohort of 198 patients with each disorders. Adjustments were made for baseline clinical and demographic variables.</div></div><div><h3>Results</h3><div>Plasma metabolomics firstly revealed uric acid as a biomarker that performs well to distinguish between phenotypically similar diseases in patients with elevated BMI. In a validation cohort of 64 patients with lipedema, uric acid (5.05 mg/dL) was compared with 64 patients with lymphedema (5.4 mg/dl), and 70 overweight patients without these conditions (4.6 mg/dL, p &lt; 0.05). Uric acid-to-cystatin c ratio distinguished between all three groups (Lipedema: 5.2; Lymphedema: 6.3; overweight: 4.0, p &lt; 0.01); however, significance was lost after adjustment for renal function.</div></div><div><h3>Conclusion</h3><div>Metabolomic analysis revealed uric acid may differentiate between lipedema, lymphedema, lipolymphedema and obese individuals without those conditions. In a validation cohort, while uric acid was higher in lipedema and lymphedema, uric acid adjusted by cystatin c clearance revealed uric acid to be a less useful marker to distinguish lipedema from lymphedema in the context of renal insufficiency.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100618"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus, Obesity and Periodontitis – A three way interconnection","authors":"Pavithra Velusamy ,&nbsp;Sri Chinthu Kenniyan Kumar ,&nbsp;Monica Charlotte Solomon","doi":"10.1016/j.obmed.2025.100615","DOIUrl":"10.1016/j.obmed.2025.100615","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) is the most common metabolic and endocrine disorder which causes a rise in blood glucose levels often attributed to insulin resistance or relative insulin insufficiency. The listed complications T2DM include retinopathy, neuropathy, nephropathy, stroke, and peripheral vascular diseases. Apart from these patients having uncontrolled and longstanding T2DM are prone to various cardiovascular disorders and oral diseases. Periodontitis, which involves inflammation of the periodontal ligament and alveolar bone has been listed as the sixth complication of diabetes mellitus for decades. Obesity is a serious social problem and is ranked as the fifth leading cause of mortality worldwide. Insulin resistance makes obesity a major risk factor for T2DM. Diabetes mellitus further adds to the periodontal tissue destruction. The hormones and cytokines in obese persons produce a series of inflammatory reactions that aid in developing periodontal disease. There are several studies linking the inflammatory triad between obesity, diabetes mellitus, and periodontitis. This review elucidates the interconnection between T2DM, obesity, and periodontitis.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100615"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between hypothyroidism and metabolic dysfunction-associated steatohepatitis in adults with obesity without diabetes","authors":"Sasha D. Macedo-Lozano ,&nbsp;Maria A. Garcia-Aguilar ,&nbsp;Gustavo Salinas-Sedo ,&nbsp;Kennlly Cardoza-Jiménez ,&nbsp;Wah Yang ,&nbsp;Ming-Hua Zheng ,&nbsp;Carlos J. Toro-Huamanchumo","doi":"10.1016/j.obmed.2025.100604","DOIUrl":"10.1016/j.obmed.2025.100604","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic dysfunction-associated steatohepatitis (MASH), often linked with obesity-related fat deposition, is increasingly prevalent as global obesity rates rise. Data from Latin America, and particularly Peru, remain limited. Research suggests that hypothyroidism may contribute to MASH development through mechanisms such as dysregulated fatty acids, elevated FGF21 concentrations, mitochondrial dysfunction, oxidative stress, and altered leptin levels, all of which may drive the associated inflammatory processes.</div></div><div><h3>Objectives</h3><div>To assess the association between hypothyroidism and MASH in adults living with obesity without a history of diabetes mellitus.</div></div><div><h3>Methods</h3><div>This cross-sectional study included adults seeking bariatric surgery at a private center in Peru. MASH was defined via biopsy results, and hypothyroidism was diagnosed based on medical history or laboratory values. The association of interest was assessed using generalized linear models to calculate prevalence ratios (PR), adjusting for confounders.</div></div><div><h3>Results</h3><div>Data from 398 patients were analyzed; the mean age was 34.3 years, and 70.6 % were female. Hypothyroidism and MASH prevalences were 9.5 % and 84 %, respectively. After adjustments for sex, age, BMI, insulin resistance, and smoking, hypothyroidism was associated with a 1.18-fold increased prevalence of MASH (adjusted PR: 1.18; 95 % CI: 1.07–1.30, p = 0.001).</div></div><div><h3>Conclusion</h3><div>Hypothyroidism was significantly associated with MASH in adults with obesity and without diabetes mellitus. This suggests a critical role of thyroid dysfunction in MASH pathogenesis, also underscoring the importance of considering thyroid health in MASH management strategies.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100604"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay of the pathophysiological mechanisms of non-alcoholic fatty liver disease, diabetes mellitus, and inflammation: A growing threat to public health","authors":"Sharon Olabisoye Oladipupo ,&nbsp;Emmanuel Henry Ezenabor ,&nbsp;Adebola Busola Ojo ,&nbsp;Akingbolabo Daniel Ogunlakin ,&nbsp;Oluwafemi Adeleke Ojo","doi":"10.1016/j.obmed.2025.100613","DOIUrl":"10.1016/j.obmed.2025.100613","url":null,"abstract":"<div><div>Non-Alcoholic Fatty Liver Disease (NAFLD), diabetes, and chronic inflammation are growing health problems that often go unnoticed, yet they are closely linked. NAFLD occurs when fat builds up in the liver, and it is strongly connected to metabolic disorders like obesity and diabetes. Over time, NAFLD can lead to insulin resistance, making diabetes worse, while diabetes itself can increase liver damage, creating a harmful cycle. Inflammation plays a key role in connecting these conditions, worsening disease progression and raising the risk of serious complications like heart disease and liver failure. Despite their widespread impact, these issues are often not diagnosed or treated early enough. This review explores how NAFLD, diabetes, and inflammation are related, their effects on public health, and new treatment options, including lifestyle changes and emerging therapies. By understanding these connections, we can develop better strategies for prevention, early detection, and treatment to improve long-term health outcomes.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100613"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Abdominal Obesity A Predictor of Pain after Laparoscopic Surgery? Insights from a cross-sectional study","authors":"Morteza Hashemian ,&nbsp;Habibeh Ahmadipour ,&nbsp;Mohammad Shafiee ,&nbsp;Alireza Shakeri ,&nbsp;Kosha Keramati ,&nbsp;Mohammad Amin Rajizadeh ,&nbsp;Ladan Amirkhosravi","doi":"10.1016/j.obmed.2025.100608","DOIUrl":"10.1016/j.obmed.2025.100608","url":null,"abstract":"<div><h3>Aim</h3><div>Postoperative pain is the most undesirable complication after surgery.Waist circumference can be a screening tool to determine overweight and abdominal obesity. Furthermore, obesity, metabolic syndrome, and pain have some proinflammatory features in common. The present study investigates the relationship between waist circumference and pain intensity after laparoscopic cholecystectomy (LC).</div></div><div><h3>Methods</h3><div>This cross-sectional study was directed at 160 candidates of LC referred to Afzalipour and Bahonar hospitals in Kerman from September to December 2022. All patients underwent general anesthesia and were operated on by the same surgery group. After each operation, the patient's clinical information form was again measured. The patient's pain level was objectively assessed based on the Visual Analog Scale (VAS) scoring system when entering the recovery (0) and 12 and 24 h later. The amount of opioids (morphine and pethidine) and other painkillers (such as NSAIDs) consumed was also extracted from the patient records.</div></div><div><h3>Results</h3><div>In this study, 70 % of the patients had abdominal obesity. The mean pain intensity score in the recovery phase was significantly higher in patients with abdominal obesity. Also, the mean pain intensity score in patients with abdominal obesity who had a history of drug abuse or non-use of drugs was higher in the recovery phase than those without abdominal obesity. The frequency of narcotic drug distribution in patients with abdominal obesity in recovery and first 12 h was higher.</div></div><div><h3>Conclusion</h3><div>The pain intensity score in patients with abdominal obesity increased during recovery. Also, obese patients consume more analgesics.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100608"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The mechanisms of obesity and its effect on female infertility","authors":"Mahla Bakhtiyari ,&nbsp;Seyed Mojtaba Heydari Khoormizi ,&nbsp;Soheila pourmasumi","doi":"10.1016/j.obmed.2025.100607","DOIUrl":"10.1016/j.obmed.2025.100607","url":null,"abstract":"<div><div>Obesity is a complex medical condition characterized by excessive body fat, which poses significant health risks and affects various physiological systems. The World Health Organization (WHO) defines obesity as a Body Mass Index (BMI) of 30 or higher. In recent decades, the prevalence of obesity has surged, emerging as a global public health crisis that intersects with various health issues, including infertility, particularly in women. This essay explores the mechanisms by which obesity impacts female fertility.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100607"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive overview of polycystic ovary syndrome: Pathophysiology, clinical features, and emerging therapeutic approaches","authors":"Larsa Naji Adam,&nbsp;Lina N. Adam","doi":"10.1016/j.obmed.2025.100606","DOIUrl":"10.1016/j.obmed.2025.100606","url":null,"abstract":"<div><div>Polycystic Ovary Syndrome (PCOS) is the leading cause of anovulatory infertility, affecting 90–95 % of women seeking fertility treatment. It is characterized by hormonal imbalances, such as elevated luteinizing hormone, androgens, and insulin, along with reduced follicle-stimulating hormone (FSH). These imbalances result in clinical features like oligomenorrhea, amenorrhea, and polycystic ovaries, and often lead to complications such as infertility, metabolic disorders, and increased cardiovascular risk. Epidemiological studies show significant regional and age-related variations in the prevalence of PCOS, highlighting the need for further research into its causes and future impact. The pathophysiology of PCOS is complex, involving genetic, endocrine, environmental, and lifestyle factors. Genetic contributors include mutations in the AR, FTO, and FSHR genes, while hyperandrogenism and insulin resistance are key endocrine disruptions. Environmental and lifestyle factors, such as diet, obesity, and exposure to endocrine-disrupting chemicals, also worsen symptoms. Clinically, PCOS presents with a range of symptoms, including menstrual irregularities, hirsutism, infertility, obesity, and associated metabolic and cardiovascular risks. The condition also significantly affects mental health and quality of life. Emerging therapies, including personalized medicine and complementary approaches, offer promise for more effective, individualized treatments. This review provides an overview of PCOS, its pathophysiology, clinical manifestations, diagnostic criteria, and management options, with the aim of informing clinical practice and guiding future research.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100606"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”","authors":"Abdullah Afridi ,&nbsp;Fathimathul Henna ,&nbsp;Umaima Cheema ,&nbsp;Ayesha Sehar ,&nbsp;Muhammad Fakhir Iftikhar Rana ,&nbsp;Areej Dar ,&nbsp;Bibi Hafza ,&nbsp;Iqra khan ,&nbsp;Laiba Ali Khan ,&nbsp;Aafeen Mujeeb ,&nbsp;Ayesha Khalid Sheikhani ,&nbsp;Insha Habib ,&nbsp;Muhammad Abdullah Ali ,&nbsp;Momina Ali ,&nbsp;Mizhgan Abid ,&nbsp;Ansar Hussain","doi":"10.1016/j.obmed.2025.100605","DOIUrl":"10.1016/j.obmed.2025.100605","url":null,"abstract":"<div><h3>Introduction</h3><div>Liraglutide, a GLP-1 receptor agonist, has been explored for its potential benefits in managing paediatric obesity. This meta-analysis aims to assess the efficacy and safety of liraglutide compared to placebo in this paediatric population with obesity.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) on liraglutide in children with obesity. Five studies with 247 participants were included. Primary outcomes included changes in BMI SDS, BMI, and body weight, and secondary outcomes included fasting serum insulin, HbA1c, fasting plasma glucose, SBP, DSP, and safety outcomes.</div></div><div><h3>Results</h3><div>The meta-analysis included five randomized controlled trials with 247 participants evaluating liraglutide in pediatric obesity. Liraglutide significantly reduced BMI SDS, with a pooled mean difference of −0.17 (p = 0.003), BMI (mean difference: 1.28, p = 0.0008), and body weight (mean difference: 1.83, p = 0.03). Secondary outcomes showed significant reductions in fasting serum insulin levels (pooled effect size: 0.39, p &lt; 0.00001), but no significant effects were observed for DSP (p = 0.29), fasting plasma glucose (p = 0.07), HbA1c (p = 0.09), or systolic blood pressure (p = 0.09). Safety analysis revealed a higher incidence of adverse events in the treatment group (risk ratio: 1.25, p = 0.18), but no significant differences were found in serious adverse events or adverse events leading to therapy discontinuation.</div></div><div><h3>Conclusions</h3><div>Liraglutide is effective in reducing BMI SDS, BMI, and body weight in pediatric obesity. While it significantly reduces fasting serum insulin levels, other secondary outcomes did not show significant changes. The safety profile of liraglutide shows a higher incidence of adverse events but no increase in serious adverse events or discontinuation rates. These findings support liraglutide's role as an effective and manageable treatment option for pediatric obesity.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100605"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring female infertility: A comprehensive review of polycystic ovary syndrome (PCOS) and its impact on reproductive health","authors":"Suparna Parua ,&nbsp;Mahuya Patra Purkait ,&nbsp;Aniruddha Bhattacharjee ,&nbsp;Rajesh Thangarajan ,&nbsp;Subramanian Rammohan ,&nbsp;Kamirul Islam ,&nbsp;Koushik Bhattacharya ,&nbsp;Alak Kumar Syamal","doi":"10.1016/j.obmed.2025.100619","DOIUrl":"10.1016/j.obmed.2025.100619","url":null,"abstract":"<div><div>Polycystic ovary syndrome (PCOS), a complicated endocrine disorder that causes female infertility, affects 6–10 % of reproductive-age women. Although it is necessary to intricate the relationship between PCOS and reproductive health to illuminate how it affects female fertility. Pathophysiology describing that how the hormonal imbalances cause ovarian cyst formation following clinical issues in ovulation. These imbalances include low FSH, high LH, and high androgens as well as increased AMH, all of which disrupt normal follicular development and ovulation. PCOS related metabolic problems such insulin resistance, obesity, and dyslipidaemia have been carefully investigated for reproductive health implications along with the pharmacological aspects. The effects of oral contraceptives, anti-androgens (such as spironolactone), and insulin-sensitizing drugs (such as metformin) on ovulation and fertility heve been reviewed. This article examines the use of the Rotterdam criteria and imaging techniques such as transvaginal ultrasound for diagnosing PCOS, while also exploring comprehensive management strategies including pharmacological treatments, alternative medicine approach and lifestyle modifications like diet and exercise to improve metabolic and reproductive outcomes. Besides those explorations of emerging treatments and early-stage studies for PCOS, including the potential of supplementary therapies like myo-inositol and lifestyle modifications tailored to individual metabolic profiles. It also highlights the latest studies on the factors contributing to PCOS and their implications for personalized treatment approaches. Emphasizing the importance of a holistic management plan, the article addresses both physical and emotional well-being, including the psychosocial impact of PCOS on mental health and overall quality of life.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100619"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protein phosphatase 6 as an important downstream target of fibroblast growth 21 and its therapeutic analogues in attenuating MASH development","authors":"Jia Nuo Feng ,&nbsp;Qingchun Tong ,&nbsp;Tianru Jin","doi":"10.1016/j.obmed.2025.100602","DOIUrl":"10.1016/j.obmed.2025.100602","url":null,"abstract":"","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"55 ","pages":"Article 100602"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}